168 completed, 40 unknown, 13 terminated, 8 withdrawn. 244 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 244 | Completed 168, Unknown 40, Terminated 13, Withdrawn 8, Not yet recruiting 6, Recruiting 5, Active not recruiting 3, Suspended 1 |
Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease Dose adjustment of statins, no dose adjustment - Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA | Phase 4 | Not yet recruiting | Rehman Medical Institute - RMI | 178 | 2026-11-01 | 2026-11-05 |
| Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia inclisiran, SOC - Acute Coronary Syndrome | Phase 4 | Not yet recruiting | Novartis Pharmaceuticals | 300 | 2026-10-31 | 2026-10-30 |
| GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis Semaglutide, Placebo (Normal Saline) - Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 396 | 2026-09-01 | 2026-06-01 |
| Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT icosapent ethyl (IPE), Standard LDL-C-Lowering Therapy - Coronary Artery Disease, Hyperlipidaemia | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 100 | 2026-08-01 | 2026-08-13 |
| A Post-Marketing Clinical Trial of Pemafibrate in Patients ο½—ith Hypercholesterolemia and Inadequate Response to Statins Pemafibrate 0.2 mg/day, Pemafibrate 0.4 mg/day, Placebo - Hypercholesterolemia | Phase 4 | Recruiting | Kowa Company, Ltd. | 120 | 2026-07-01 | 2026-07-13 |
| Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention Inclisiran, Alirocumab - Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 4 | Recruiting | University Medical Centre Ljubljana | 60 | 2026-05-18 | 2026-06-02 |
| Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome Atorvastatin 40 Mg Oral Tablet, Ezetimibe 10 mg, Bempedoic Acid 180 MG Oral Tablet - Acute Coronary Syndromes (ACS), Hypercholesterolemia | Phase 4 | Not yet recruiting | Punjab Institute of Cardology | 120 | 2026-05-01 | 2026-04-09 |
| Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT Live Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE), Standard Care (in control arm) - Hypertriglyceridemic Acute Pancreatitis, Acute Pancreatitis, Hypertriglyceridemia-induced | Phase 4 | Recruiting | Jianyin Zhou | 180 | 2026-01-18 | 2026-07-22 |
| Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol Rosuvastatin + Ezetimibe, Bempedoic Acid + Ezetimibe, Rosuvastatin + Ezetimibe + Bempedoic Acid - Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol | Phase 4 | Completed | Bahria University | 126 | 2026-01-01 | 2026-10-20 |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo) - Percutaneous Coronary Intervention, Peripheral Endovascular Intervention | Phase 4 | Recruiting | Duke University | 6000 | 2025-07-23 | 2026-10-29 |
| A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan Bempedoic acid 180 mg tablet - Primary Hypercholesterolemia or Mixed Hyperlipidemia | Phase 4 | Completed | Daiichi Sankyo | 180 | 2025-04-01 | 2025-12-08 |
| LATAM LOWERS LDL-C Usual care, KJX839 - Hypercholesterolaemia | Phase 4 | Recruiting | Novartis Pharmaceuticals | 520 | 2025-02-11 | 2025-12-30 |
| Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population Atorvastatin 10 mg and ezetimibe 10 mg, Atorvastatin 20 mg - Hyperlipidemia (E.G., Hypercholesterolemia) | Phase 4 | Withdrawn | Dr. Md. Alimur Reza | 2025-02-01 | 2026-10-07 | |
| VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease Inclisiran - Atherosclerotic Cardiovascular Disease | Phase 4 | Active not recruiting | Duke University | 130 | 2024-12-16 | 2026-07-29 |
| Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound Inclisiran - Carotid Plaque, Hyperlipidemia | Phase 4 | Unknown | First Affiliated Hospital of Xinjiang Medical University | 40 | 2024-09-20 | 2024-09-19 |
| A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. Inclisiran sodium, BPA - Hypercholesterolemia | Phase 4 | Completed | Novartis Pharmaceuticals | 402 | 2024-06-21 | 2026-07-29 |
| Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes EPAVasc, Corn Oil - Diabetes Type 2, Hypertriglyceridemia | Phase 4 | Unknown | University of Ioannina | 450 | 2023-12-01 | 2023-11-15 |
| Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides Pitavastatin 4mg, Ezetimibe 10 mg, Placebo (for Pitavastatin/Ezetimibe) - Hypercholesterolemia | Phase 4 | Active not recruiting | JW Pharmaceutical | 88 | 2023-08-21 | 2026-03-02 |
| EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) moderate- or high-intensity statin/ rosuvastatin - Lipid Disorder | Phase 4 | Completed | Wake Forest University Health Sciences | 22 | 2023-03-08 | 2026-10-02 |
Showing 20 of 244. Sign in to see all of them.
Hypercholesterolemia (148) · Hypertriglyceridemia (35) · Cardiovascular Diseases (24) · Atherosclerosis (21) · Dyslipidemias (21) · Coronary Artery Disease (18) · Diabetes Mellitus (17) · Diabetes Mellitus, Type 2 (17) · Hypertension (16) · Insulin Resistance (14) · Coronary Disease (13) · Hyperlipoproteinemia Type II (12) · HIV Infections (8) · Inflammation (8)
Nutritional and Metabolic Diseases (244) · Metabolic Diseases (243) · Lipid Metabolism Disorders (240) · Dyslipidemias (223) · Vascular Diseases (73) · Cardiovascular Diseases (63) · Glucose Metabolism Disorders (47) · Arterial Occlusive Diseases (39) · Arteriosclerosis (39) · Myocardial Ischemia (35) · Heart Diseases (34) · Endocrine System Diseases (32) · Pathological Conditions, Signs and Symptoms (29) · Urogenital Diseases (19)
Atorvastatin (46) · Ezetimibe (40) · Rosuvastatin Calcium (30) · Simvastatin (26) · Fenofibrate (13) · Omacor (12) · evolocumab (11) · Ezetimibe, Simvastatin Drug Combination (10) · Pravastatin (10) · pitavastatin (10) · Colesevelam Hydrochloride (8) · Amlodipine (7) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (7) · ALN-PCS (6) · Niacin (6)
Organon and Co (18) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (12) · Gachon University Gil Medical Center (9) · Daiichi Sankyo (7) · AstraZeneca (6) · Yonsei University (5) · JW Pharmaceutical (4) · Novartis Pharmaceuticals (4) · Seoul National University Hospital (4) · Duke University (3) · Amgen (2) · Brigham and Women's Hospital (2) · Bronx VA Medical Center (2) · Danish HIV Research Group (2) · GlaxoSmithKline (2)
United States (58) · South Korea (33) · Japan (15) · China (11) · Italy (11) · Canada (8) · Germany (8) · France (7) · Spain (7) · Taiwan (6) · Mexico (5) · United Kingdom (5) · Austria (4) · Belgium (4) · Denmark (4)
Ann-Brit E Hansen, M.D. (2) · Court Pedersen, Professor (2) · Jan Gerstoft, M.D., DMSc (2) · Lawrence Baruch, MD (2) · Ronald M Krauss, M.D. (2) · Aaron I Vinik, MD, PhD (1) · Adrian S Dobs, MD (1) · Alex Laursen, D.M., DMSc (1) · Alex Laursen, M.D., DMSc (1)
PMID 38018702, PMID 10323786, PMID 10593347, PMID 11009277, PMID 11558482, PMID 11781675, PMID 11849859, PMID 12379573, PMID 12652104, PMID 15505289, PMID 16310551, PMID 16404415, PMID 16749654, PMID 16893434, PMID 16923260, PMID 17011942, PMID 17407633, PMID 17578790, PMID 17668878, PMID 17711927, PMID 17898099, PMID 18172039, PMID 18332269, PMID 18398080, PMID 18404599, PMID 18519429, PMID 18545068, PMID 18559695, PMID 18762410, PMID 18955731, PMID 19060422, PMID 19095139, PMID 19104004, PMID 19116237, PMID 19167589, PMID 19286582, PMID 19407658, PMID 19423108, PMID 19597368, PMID 19608026, PMID 19651918, PMID 19820283, PMID 19879596, PMID 19939653, PMID 19967051, PMID 20067513, PMID 20298928, PMID 20339536, PMID 20413733, PMID 20467151
2004 (1), 2005 (1), 2015 (1), 2016 (1), 2018 (1), K23AT002862 (1), K23HL169929 (1), R01AR071263 (1), R01DK061486 (1), R01HL075824 (1), R01MH071536 (1)